Fourth COVID-19 Shot Beneficial in Patients With Autoimmune Rheumatic Diseases
By Elana Gotkine HealthDay Reporter
TUESDAY, Nov. 28, 2023 -- For patients with systemic autoimmune rheumatic diseases using disease-modifying antirheumatic drugs (DMARDs), receiving a fourth COVID-19 mRNA vaccine reduces the risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, according to a study published online Nov. 15 in The Lancet Rheumatology.
Jennifer S. Hanberg, M.D., from Brigham and Women's Hospital in Boston, and colleagues conducted an emulated target trial using observational data to compare receiving versus not receiving a fourth mRNA vaccine dose among patients with systemic autoimmune rheumatic diseases who were prescribed DMARDs. Data were included for 4,305 patients: 3,126 received a fourth dose, and 1,179 did not. After emulation of the time-sequential once-per-week trials and overlap propensity score weighting, both groups included 2,563 adults.
Of the 2,563 participants, 54.3 percent had rheumatoid arthritis; the most frequent treatments used were conventional synthetic DMARDs and biological DMARDs (58.1 and 39.3 percent, respectively). The researchers found that the risk for SARS-CoV-2 was lower among patients receiving versus not receiving a fourth vaccine dose (hazard ratio [HR], 0.59). The risk for admission to hospital or death within –3 to +14 days of SARS-CoV-2 infection was also lower with receipt of a fourth vaccine dose (HR, 0.35).
"Patients with systemic autoimmune rheumatic diseases should be encouraged to receive at least four doses of mRNA vaccines," the authors write.
Several authors disclosed ties to the biopharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted November 2023
Further Support and Information on COVID-19
Read this next
No Association Found for Autoimmune Disease, Monoclonal Gammopathy
MONDAY, May 20, 2024 -- In a systematically screened population, there is no association between autoimmune disease and monoclonal gammopathy of undetermined significance (MGUS)...
Rheumatology Workforce Increased 20 Percent From 2009 to 2019
THURSDAY, March 14, 2024 -- The overall number of clinically active rheumatology providers grew more than 20 percent during the last decade, according to a study published online...
Risk for Autoimmune Inflammatory Rheumatic Disease Increased After SARS-CoV-2
TUESDAY, March 5, 2024 -- Patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have an increased risk for incident autoimmune inflammatory...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.